Acute Myeloid Leukemia Clinical Trials

The purpose of this study is to identify the most appropriate dose that can be safely administered and that can have an effect on blood cancer cells. Once that safe dose is identified, additional patients will be asked to join the study to further evaluate the safety and effectiveness of ...

To determine the maximum tolerated and / or recommended Phase II dose of oral mutant IDH1 (mIDH1) inhibitor BAY1436032 and to characterize its safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical efficacy in patients with mIDH1-R132X advanced acute myeloid leukemia (AML)

For more information please visit: http://clinicaltrials.gov/ct2/show/NCT01307579?term=Children%27s+Oncology+Group&cond=Prevent+Invasive+Fungal+Infection+in+Children+Undergoing+Chemotherapy+for+Acute+Myeloid+Leukemia+%28AML%29&rank=1

People with acute myeloid leukemia are asked to participate in a research study being conducted by Montefiore Medical Center

People with acute myeloid leukemia are asked to participate in a research study being conducted by Montefiore Medical Center.

People with Acute Myeloid Leukemia are asked to participate in a research study being conducted by Montefiore Medical Center.

This randomized phase III trial studies how well bortezomib and sorafenib tosylate work in treating patients with newly diagnosed acute myeloid leukemia. Bortezomib and sorafenib tosylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy work in different ...

People with Relapsed/Refractory Acute Myeloid Leukemia are asked to participate in a research study being conducted by North Shore University Hospital.

A registry trial for Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease

In Stage 1 of the study, all eligible AML patients with demonstrated NOXA BH3 priming of 40% by mitochondrial profiling in bone marrow will receive treatment with alvocidib, cytarabine and mitoxantrone [ACM ('FLAM') regimen]. In Stage 2, all eligible AML patients with demonstrated NOXA BH3 priming of 40% by mitochondrial ...